Senseonics Holdings Inc. (SENS) saw its stock surge 5.07% during intraday trading on Friday, reflecting strong investor optimism following the company's strategic acquisition announcement.
The medical technology company entered into a Master Asset Purchase Agreement with Ascensia Diabetes Care Holdings AG to acquire U.S. assets related to the marketing, selling, and distribution of the Eversense® continuous glucose monitoring (CGM) system. The deal, which closed on January 1, 2026, also includes plans for Senseonics to expand its footprint in Europe by acquiring additional Eversense-related assets in Italy, Germany, Spain, and Sweden by mid-2026, pending regulatory approvals.